Phaseline

Targets › CYP3A4

CYP3A4 (Cytochrome P450 3A4): drug programs, companies and trials

11 programs from 11 companies in 14 trials: 6 Phase 4, 3 Phase 2, 3 Phase 1, 2 Phase 3; Infectious disease, Oncology; next expected readout Nov 2026.

A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). (UniProt, P08684)

Open in Phaseline: the race on CYP3A4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
José Antonio Mata MarínDarunavir
Human immunodeficiency virus type 1 protease inhibitor
CYP3A4, POLBPhase 4HIV InfectionNov 2026
Instituto Mexicano del Seguro SocialDarunavir
Human immunodeficiency virus type 1 protease inhibitor
PROT, CYP3A4, POLR2APhase 4HIV InfectionDec 2026
Mount Sinai Hospital, CanadaRitonavir
Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor
CYP3A4, CYP3A5, CYP3A43, CYP3A7Phase 4SARS CoV-2 Post-Acute SequelaeJan 2027
Gilead SciencesCobicistat
Cytochrome P450 3A inhibitor
CYP3A4, CYP3A5, CYP3A43, CYP3A7Phase 4HIV-1-infection; AML, AdultJun 2027
Nanjing First Hospital, Nanjing Medical UniversityVonoprazan-Amoxicillin Dual Therapy
Potassium-competitive acid blocker combined with beta-lactam antibiotic for H. pylori erad
CYP3A4Phase 4HELICOBACTER PYLORI INFECTIONS–
University of OxfordRitonavir
Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor
CYP3A4, CYP3A5, CYP3A43, CYP3A7Phase 3Pneumonia; COVID-19Jan 2027
Haukeland University HospitalRitonavir
Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor
CYP3A4, CYP3A5, CYP3A43, CYP3A7Phase 3Post COVID-19 Condition, UnspecifiedJun 2027
Harvard School of Public Health (HSPH)Ritonavir
Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor
CYP3A4, CYP3A5, CYP3A43, CYP3A7Phase 2HIVJun 2029
Anthony Joshua, FRACPItraconazole
Cytochrome P450 51 inhibitor
CYP3A4Phase 1Ovarian CancerJan 2027
University of Wisconsin, MadisonRitonavir
Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor
CYP3A4, CYP3A5, CYP3A43, CYP3A7Phase 1High-Grade Anal Intraepithelial NeoplasiaJun 2027
University of MiamiRitonavir
Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor
CYP3A4, CYP3A5, CYP3A43, CYP3A7Phase 1High Grade GliomaApr 2029

Conditions

HIV Infection (3) HIV (1) High-Grade Anal Intraepithelial Neoplasia (1) Post COVID-19 Condition, Unspecified (1) Ovarian Cancer (1) HELICOBACTER PYLORI INFECTIONS (1) SARS CoV-2 Post-Acute Sequelae (1) Pneumonia (1) COVID-19 (1) HIV-1-infection (1) AML, Adult (1) High Grade Glioma (1)

Modalities

small molecule (9), mixed (2)

Companies

Instituto Mexicano del Seguro Social (1) Harvard School of Public Health (HSPH) (1) University of Wisconsin, Madison (1) Haukeland University Hospital (1) Anthony Joshua, FRACP (1) Nanjing First Hospital, Nanjing Medical University (1) Mount Sinai Hospital, Canada (1) José Antonio Mata Marín (1) University of Oxford (1) Gilead Sciences (1) University of Miami (1)

Related targets

CYP3A5 (7) CYP3A43 (7) CYP3A7 (7) PROT (1) POLR2A (1) POLB (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.